Genelux Investor Presentation Deck

Creating a New Paradigm Of Oncolytic Virus Drug Development GENELUX Our Advantage GENELUX Systemic Dosing and Redosing Target & Treat Metastatic Diseases 7 completed clinical trials ~150 patients AMGEN T-VEC (approved) in melanoma gains first clinical and regulatory validation of an oncolytic virus Robust Immune Activation Profile Broad spectrum of accessible tumor types Replimune® RP1 (registration directed trials) in skin cancer BCG ONCOLOGY CG0070 (Phase 3) in patients with non- muscle invasive bladder cancer unresponsive to BCG Olvi-Vec Our New Generation Olvi-Vec has the potential to redefine the oncolytic virus space and provide utility across multiple tumor types by enabling physician- preferred administration techniques and setting new benchmarks in efficacy and safety, as shown in multiple clinical trials. Genelux looks to its Phase 3 trial to potentially bring a best-in-class therapy to those patients in need. 1st Gen Viruses Commercial/Late-stage 1st Generation viruses confirm modality's potential, but all are limited to local delivery and scope of addressable cancers 10

View entire presentation